Gainers
- Epizyme EPZM shares increased by 7.3% to $1.32 during Tuesday's after-market session. Epizyme's trading volume hit 240.6K shares by close, accounting for 10.7% of its average volume over the last 100 days. The company's market cap stands at $140.0 million.
- Viking Therapeutics VKTX stock moved upwards by 6.52% to $4.08. Trading volume for this security closed at 108.0K, accounting for 11.5% of its average full-day volume over the last 100 days. The company's market cap stands at $319.1 million.
- Agile Therapeutics AGRX stock rose 3.28% to $0.39. The market value of their outstanding shares is at $47.3 million.
- Enveric Biosciences ENVB shares rose 3.04% to $0.68. The market value of their outstanding shares is at $22.1 million.
- Celsion CLSN stock increased by 2.89% to $0.48. The market value of their outstanding shares is at $41.5 million.
- Gritstone Bio GRTS shares moved upwards by 2.89% to $5.68. The company's market cap stands at $386.1 million.
Losers
- PetVivo Holdings PETV shares fell 4.4% to $1.3 during Tuesday's after-market session. The company's market cap stands at $12.6 million.
- Quantum-Si QSI shares decreased by 3.53% to $4.65. The market value of their outstanding shares is at $638.9 million.
- Immix Biopharma IMMX shares declined by 3.48% to $4.45. The company's market cap stands at $33.7 million.
- Biofrontera BFRI shares fell 3.03% to $4.17. Trading volume for this security closed at 127.9K, accounting for 0.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $62.7 million.
- PharmaCyte Biotech PMCB shares declined by 2.87% to $2.2. The company's market cap stands at $45.5 million.
- Gilead Sciences GILD stock decreased by 2.77% to $66.58. Gilead Sciences's trading volume hit 692.7K shares by close, accounting for 8.8% of its average volume over the last 100 days. The company's market cap stands at $83.5 billion. As per the press release, Q4 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in